Abbott Medical Optics is focused on delivering life-improving vision technologies to people of all ages. The company offers a comprehensive portfolio of cataract, refractive and eye care products. Abbott Medical Optics is headquartered in Santa Ana, California, employing approximately 4,000 worldwide.
We are a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Glaucoma is one of the largest segments in the global ophthalmic market.
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Alcon’s three businesses, Surgical, Pharmaceutical and Vision Care, offer the widest spectrum of eye care products in the world. Alcon is the second-largest division of the Novartis Group, with pro-forma sales of USD 10.8 billion in 2014.
ALPHAEON Corporation is a social commerce company with the goal of transforming self-pay healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty and performance. The company works in partnership with board certified physicians ensuring access to leading advancements in lifestyle healthcare.
Ora is the world’s leading independent, full-service ophthalmic CRO and product development firm. Over the past 30 years, we helped our clients earn 34 FDA approvals. We support a wide array of organizations, from start-ups to global device and pharmaceutical companies, to efficiently and successfully bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies and regulatory strategies have been refined across thousands of projects both in the US and internationally. We bring together the world’s most extensive and experienced network of ophthalmic experts and R&D professionals to maximize the value of new product initiatives.
Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and are developing treatments for symptomatic conditions in Ophthalmics.
Avedro is a privately held medical device and pharmaceutical company which is developing corneal cross-linking, a non-invasive treatment for refractive disorders and certain pathologies. Avedro sells its products outside the US in 62 countries and has submitted an NDA to the FDA under orphan designation for its cross-linking system for keratoconus. Avedro is also developing a next generation cross-linking technology, Photorefractive Intrastromal Cross-Linking (PiXL™), which is customized for each patient’s topography. Avedro believes that PiXL is an application for post-cataract ametropia and refractive correction, and has an annual potential of 10 million procedures. Avedro is based in Waltham, Massachusetts.
Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.
Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye.
AcuFocus Inc. is an ophthalmic medical device company that develops breakthrough technologies for the improvement of near vision. AcuFocus also distributes the AcuTarget HD diagnostic and surgical planning instrument. This instrument is essential for the optimal treatment and technology selection for a broad range of patients, including LASIK, cataract, dry eye and presbyopes.
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight. Bausch + Lomb is a global hallmark for innovation and quality, offering the widest and finest range of eye health products including ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments.
Envisia Therapeutics is an innovative biotechnology company that is leveraging the proprietary PRINT® technology to address critical unmet needs in ophthalmology. Beginning with ENV515, an investigational product that could redefine glaucoma treatment, Envisia aims to change the therapeutic landscape of ophthalmology by engineering a pipeline of innovative products.
ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major eye diseases. The lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually.
InnFocus MicroShunt® addresses the largest glaucoma patient segment and has achieved mean post op IOP’s below 15 mm Hg, and 80% med reduction. IOP reduction at 3 months similar to 3 year. Over 35 doctors have treated more than 240 patients in 7 countries, followed for up to 5 years.
Kala is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus.
LacriScience is in late stage development of its LacriPen, a portable instrument using gold plated single-use sensors, that measures osmolarity to +/- 2 mOSM/L and proteins. By coating the gold film with a specific antibody, such as Adenovirus, Herpes Zoster, Herpes Simplex, or any biomaker, it can be precisely identified or quantified instantly.
MicroOptx is developing a revolutionary MIGs implant utilizing proprietary surface chemistries and nanotechnology to shunt aqueous humor directly to the surface of the eye. By not shunting to other, enclosed spaces within the eye, the rate of aqueous outflow is precisely controlled to consistently achieve IOP below threshold.
Product – ZeptoTM is a disposable automated capsulotomy device that provides surgeons with consistent, well-centrated, and accurate capsulotomies without interrupting surgical routine and patient flow. ZeptoTM uses a highly focused, fast multipulse low energy discharge to instantaneously produce a perfectly round anterior capsulotomy simultaneously everywhere along 360 degrees.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases of the eye using its proprietary hydrogel platform technology. The Company’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and allergic conjunctivitis, and Phase 2 for glaucoma and inflammatory dry eye disease. The Company is also evaluating sustained-release anti-VEGF depots. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
PowerVision has developed a fluid-controlled accommodating IOL designed to restore youthful vision. The FluidVision™ AIOL provides True Accommodation™ by mimicking the eye’s natural accommodative process to transport fluids inside it, creating true shape change. The Company has shown in clinical trials that it can deliver clear vision at all distances.
ReVision Optics®, Inc. is developing and commercializing an innovative optical solution to correct presbyopic vision, or the inability of the eye to focus on near objects.
Emmetrope has developed a line of accommodating IOLs that is based on a proprietary hinge design. The single optic version, ActaLens™, is already in clinical testing with verification of accommodation. ActaLens is injected through a sutureless corneal incision, placed in-the-bag, and has a robust mechanism that is independent of capsular elasticity.
Glaucoma Research Foundation (GRF) is a national nonprofit founded in 1978 in San Francisco to encourage innovative research toward better treatments for people with glaucoma. GRF has funded more than $50 million of grants and projects in 35 years. In addition to advancing innovation in glaucoma research, GRF provides education and support for people with glaucoma and sponsors catalyst meetings like the annual Glaucoma 360 New Horizons Forum to foster collaboration and speed the cure. The Glaucoma Research Foundation mission is to prevent vision loss from glaucoma by investing in innovative research, education, and support with the ultimate goal of finding a cure.
Ophthalmic Women Leaders (OWL) is the preeminent nonprofit organization for the professional development and advancement of women in the eye care industry. Representing women in every part of ophthalmology—from clinical roles to media, marketing and sales, to research and finance—OWL offers opportunities for women to build the leadership skills necessary to excel in their careers and lives. In addition to leadership development programs and networking events, OWL also offers live webinars, on-demand content, workshops and presentations at major industry meetings, roundtable discussions, and a coaching and mentoring program. Membership is open to all.
Bryn Mawr Communications’ eye care publications are uniquely positioned within the ophthalmic marketplace to serve both physicians’ and industry’s needs. Cataract & Refractive Surgery Today, Cataract & Refractive Surgery Today Europe, Advanced Ocular Care, Retina Today, and Glaucoma Today provide TARGETED CONTENT FOR A CLEARLY DEFINED AUDIENCE. The publications are comprehensive editorial packages that suit ophthalmologists’ and optometrists’ specific interests. Our how-to format promotes continuing education with topics such as the latest surgical approaches and techniques, best practices in integrated care, complications management and avoidance pearls, practice management and business advice, and the latest technological advances. Our publications are not only concerned with what’s now but also what’s next. Our readers are looking for the latest in product releases and technological developments, both in the United States and internationally. Surgeons investing in a technology want to know what its long-term benefits will be, so we look beyond clinical approvals into potential future applications.
Ethis began in the mid 1990s as a print publisher with a single focus: to bring clearly written, carefully reasoned content to all corners of the eyecare industry. Today, our robust publishing and marketing efforts bring our signature quality content to traditional and digital platforms. Our reach has expanded, but our focus is the same: from the tear film to the macula, we have eyecare covered. We bring more than 18 years of experience creating and publishing clear, thoughtful content about the clinical and practical aspects of eyecare. Over the years we have also developed solid relationships with thought leaders and industry players, enabling us to provide timely, accurate communication in all media and across the full gamut of eyecare topics.
As the news and feature magazine of the American Society of Cataract & Refractive Surgery, EyeWorld serves as the premier publication for anterior segment surgeons. The magazine provides comprehensive ophthalmic news and the latest clinical information in the areas of cornea, glaucoma, cataract, and refractive surgery, as well as periodic updates on retinal issues. Each article is carefully reviewed by the editorial staff, the article’s sources, and the medical editors before its publication. EyeWorld draws from ASCRS’ highly esteemed membership to create the finest editorial board of any publication in the industry.
Healio.com, the online home of Ocular Surgery News, offers daily news updates, online only content, extensive CME and specialized email News Wires. Download the new Healio.com/Ocular Surgery News App on iTunes- Search “Ocular Surgery News.” As the best-read newspaper for ophthalmologists, Ocular Surgery News holds a unique place among the eye care publications. With the largest dedicated staff focused solely on ophthalmology, OSN strives to bring our readers a deeper understanding of the news and events that affect their profession.
US Ophthalmic Review and European Ophthalmic Review enables time-pressured physicians to stay abreast of key advances and opinion in ophthalmic practice in the US and Europe. The journal comprises balanced and comprehensive articles written by leading authorities addressing the most important and salient developments in the ophthalmic field. The journal endeavours to support physicians and related healthcare professionals in continuously developing their knowledge and effectiveness. Guided by an Editorial Board comprising world-renowned experts in their respective sub-specialties, the journal’s editorial policy is designed to promote best practice and encourage discussion among practising professionals in the field.
Clarus Ventures is a global investment firm dedicated to life sciences. Founded in 2005, our Portfolio includes public and private companies in the biotechnology, diagnostics, tools and medical device spaces. Clarus is presently managing $1.6 billion.
For over 35 years InterWest has partnered with entrepreneurs to build award winning healthcare and technology companies. As we complete investing InterWest X, a $650M fund, we continue to believe that providing capital is just the beginning of a long-term collaboration with entrepreneurs to turn their vision into a thriving compan
Morgenthaler Ventures is a premier venture capital firm, dedicated to helping entrepreneurs build valuable companies. The Morgenthaler Life Science Team consists of a highly experienced group of investors and operators who have invested and directed the exits of some of the largest venture-backed deals since 2000.
SV Life Sciences is a global leader in healthcare investing. SVLS employs a diversified strategy within healthcare and generally targets early stage opportunities in biotechnology, a combination of early and expansion stage deals in medical devices and growth equity opportunities within the healthcare services and healthcare information technology segments.
Versant Ventures is a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, nearly 50 Versant companies have achieved successful acquisitions or IPOs.